439 related articles for article (PubMed ID: 23129509)
1. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.
Wöhrle S; Henninger C; Bonny O; Thuery A; Beluch N; Hynes NE; Guagnano V; Sellers WR; Hofmann F; Kneissel M; Graus Porta D
J Bone Miner Res; 2013 Apr; 28(4):899-911. PubMed ID: 23129509
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice.
Xiao L; Du E; Homer-Bouthiette C; Hurley MM
Endocrinology; 2017 Oct; 158(10):3629-3646. PubMed ID: 28938491
[TBL] [Abstract][Full Text] [Related]
3. Osteocytes and the pathogenesis of hypophosphatemic rickets.
Yamazaki M; Michigami T
Front Endocrinol (Lausanne); 2022; 13():1005189. PubMed ID: 36246908
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization.
Liu S; Gupta A; Quarles LD
Curr Opin Nephrol Hypertens; 2007 Jul; 16(4):329-35. PubMed ID: 17565275
[TBL] [Abstract][Full Text] [Related]
6. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
Fukumoto S
Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
[TBL] [Abstract][Full Text] [Related]
7. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.
Martin A; Liu S; David V; Li H; Karydis A; Feng JQ; Quarles LD
FASEB J; 2011 Aug; 25(8):2551-62. PubMed ID: 21507898
[TBL] [Abstract][Full Text] [Related]
8. Impaired Growth Plate Maturation in XLH Is due to Both Excess FGF23 and Decreased 1,25-Dihydroxyvitamin D Signaling.
Yadav PS; Kobelski MM; Martins JS; Tao T; Liu ES; Demay MB
Endocrinology; 2023 Nov; 165(1):. PubMed ID: 38066669
[TBL] [Abstract][Full Text] [Related]
9. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Rowe PS
Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
[TBL] [Abstract][Full Text] [Related]
10. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.
Goldsweig BK; Carpenter TO
Curr Osteoporos Rep; 2015 Apr; 13(2):88-97. PubMed ID: 25620749
[TBL] [Abstract][Full Text] [Related]
11. Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in
Xiao Z; Liu J; Liu SH; Petridis L; Cai C; Cao L; Wang G; Chin AL; Cleveland JW; Ikedionwu MO; Carrick JD; Smith JC; Quarles LD
Mol Pharmacol; 2021 Jun; 101(6):408-421. PubMed ID: 35339985
[TBL] [Abstract][Full Text] [Related]
12. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
13. Eldecalcitol Causes FGF23 Resistance for Pi Reabsorption and Improves Rachitic Bone Phenotypes in the Male Hyp Mouse.
Kaneko I; Segawa H; Ikuta K; Hanazaki A; Fujii T; Tatsumi S; Kido S; Hasegawa T; Amizuka N; Saito H; Miyamoto KI
Endocrinology; 2018 Jul; 159(7):2741-2758. PubMed ID: 29878089
[TBL] [Abstract][Full Text] [Related]
14. 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.
Liu ES; Martins JS; Raimann A; Chae BT; Brooks DJ; Jorgetti V; Bouxsein ML; Demay MB
J Bone Miner Res; 2016 May; 31(5):929-39. PubMed ID: 26751835
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.
Aono Y; Yamazaki Y; Yasutake J; Kawata T; Hasegawa H; Urakawa I; Fujita T; Wada M; Yamashita T; Fukumoto S; Shimada T
J Bone Miner Res; 2009 Nov; 24(11):1879-88. PubMed ID: 19419316
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.
Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD
Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691
[TBL] [Abstract][Full Text] [Related]
17. Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation.
Farrow EG; Summers LJ; Schiavi SC; McCormick JA; Ellison DH; White KE
J Endocrinol; 2010 Oct; 207(1):67-75. PubMed ID: 20675303
[TBL] [Abstract][Full Text] [Related]
18. FGFR Inhibitor Ameliorates Hypophosphatemia and Impaired Engrailed-1/Wnt Signaling in FGF2 High Molecular Weight Isoform Transgenic Mice.
Du E; Xiao L; Hurley MM
J Cell Biochem; 2016 Sep; 117(9):1991-2000. PubMed ID: 26762209
[TBL] [Abstract][Full Text] [Related]
19. Advances in understanding of phosphate homeostasis and related disorders.
Michigami T
Endocr J; 2022 Aug; 69(8):881-896. PubMed ID: 35831119
[TBL] [Abstract][Full Text] [Related]
20. Elevated fibroblast growth factor 23 exerts its effects on placenta and regulates vitamin D metabolism in pregnancy of Hyp mice.
Ohata Y; Yamazaki M; Kawai M; Tsugawa N; Tachikawa K; Koinuma T; Miyagawa K; Kimoto A; Nakayama M; Namba N; Yamamoto H; Okano T; Ozono K; Michigami T
J Bone Miner Res; 2014 Jul; 29(7):1627-38. PubMed ID: 24470103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
